You are here: Industry Insights > Roche

News List

Roche announces positive results of lung cancer drug Tecentriq biospectrumasia
July 05, 2018
The combination of Tecentriq plus chemotherapy Abraxane, as an initial (first-line) treatment, significantly reduced the risk of disease
Roche and Foundation Medicine reach definitive merger agreement to accelerate broad availability of comprehensive genomic profiling in oncology worldpharmanews
July 05, 2018
Roche (SIX: RO, ROG; OTCQX: RHHBY) and Foundation Medicine, Inc. (NASDAQ: FMI) have entered into a definitive merger agreement for Roche to acquire the outstanding shares of FMI's common stock not already owned by Roche and its affiliates at a price of US
Roche commences tender offer for all shares of Foundation Medicine, Inc. for US$ 137.00 per share in cash worldpharmanews
July 05, 2018
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that it has commenced a cash tender offer for all of the outstanding shares of common stock of Foundation Medicine, Inc.
NICE ‘no’ for Roche’s Ocrevus in primary progressive MS pharmatimes
July 03, 2018
The National Institute for Health and Care Excellence has concluded that Roche’s Ocrevus should not be funded on the NHS for the treatment of primary progressive multiple sclerosis (PPMS) in adults.
Roche gearing up to file Tecentriq for breast cancer pharmatimes
July 03, 2018
Roche has unveiled data showing that a combination of Tecentriq and Abraxane significantly slashed the risk of disease worsening or death in some breast cancer patients.
Kymab, Roche Partner to Evaluate KY1044 contractpharma
July 03, 2018
Kymab Group Ltd has entered a clinical trial agreement with Roche. Under the agreement, Roche will provide its PD-L1 blocking antibody atezolizumab for use in combination in Kymab’s upcoming Phase I-II clinical studies combining
Roche buys Foundation Medicine for $2.4 billion financialexpress
June 29, 2018
Swiss drugmaker Roche is paying $2.4 billion to buy the rest of Foundation Medicine (FMI), raising its bet on the US genomic profiling group’s ability to personalise cancer care.
Roche to buy remaining stake in Foundation Medicine for $2.4bn pharmaceutical-technology
June 28, 2018
Roche has signed a definitive agreement to acquire the outstanding shares of Foundation Medicine (FMI) for $2.4bn.
The first single-dose flu drug nod could be FDA’s Christmas present for Roche fiercepharma
June 27, 2018
When Shionogi got Japanese approval for its novel flu drug Xofluza (baloxavir marboxil) in February, it didn’t expect a U.S. decision in 2018. Now, an FDA priority review has made it possible for its partner Roche to get a go-ahead before New Year's.
Roche appoints James Sabry as global partnering head biospectrumasia
June 26, 2018
Sabry succeeds Sophie KornowskiBonnet, Head of Roche Partnering and member of the enlarged Corporate Executive Committee since 2012.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 45 46 Next page